ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours

AbbVie has announced positive data for its antibody-drug conjugate (ADC) therapies, Teliso-V, ABBV-400 and ABBV-706, from Phase I and II trials in solid tumour indications.

The results were presented during the ongoing American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago until 4 June.